Clinical/Translational Cancer Immunotherapy

Section edited by Dr. James L. Gulley

First-in-man clinical trials, phase II/III clinical studies, immune monitoring investigations, tumor microenvironment, host genetics and clinical outcome, combination therapies, and cell therapies.

Previous Page Page 2 of 4 Next Page
  1. Research article

    Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients

    Tumor response characteristics using immune-related RECIST1.1 (irRECIST1.1) in advanced non-small-cell lung cancer (NSCLC) patients treated with nivolumab monotherapy in the clinical setting have not been prev...

    Mizuki Nishino, Nikhil H. Ramaiya, Emily S. Chambers, Anika E. Adeni, Hiroto Hatabu, Pasi A. Jänne, F. Stephen Hodi and Mark M. Awad

    Journal for ImmunoTherapy of Cancer 2016 4:84

    Published on: 20 December 2016

  2. Research article

    A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma

    Ipilimumab and peginterferon alfa-2b are established systemic treatment options for melanoma that have distinct mechanisms of action. Given the need for improved therapies for advanced melanoma, we conducted a...

    Andrew S. Brohl, Nikhil I. Khushalani, Zeynep Eroglu, Joseph Markowitz, Ram Thapa, Y. Ann Chen, Ragini Kudchadkar and Jeffrey S. Weber

    Journal for ImmunoTherapy of Cancer 2016 4:85

    Published on: 20 December 2016

  3. Research article

    Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors

    We evaluated whether tumor infiltrating lymphocytes (TIL) could be expanded from surgically resected tumors from pancreatic cancer patients.

    MacLean Hall, Hao Liu, Mokenge Malafa, Barbara Centeno, Pamela J. Hodul, José Pimiento, Shari Pilon-Thomas and Amod A. Sarnaik

    Journal for ImmunoTherapy of Cancer 2016 4:61

    Published on: 18 October 2016

  4. Meeting report

    Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge”, Napoli, December 5th 2015

    Harnessing the immune system and preventing immune escape, the immunotherapy of cancer provides great potential for clinical application, in broad patient populations, achieving both conventional and unconvent...

    Paolo A. Ascierto, Maria Libera Ascierto, Silvia Formenti, Sacha Gnjatic, Hans Hammers, Vera Hirsh, Rolf Kiessling, Ignacio Melero, Rita Nanda, Graham Pawelec, Sandro Pignata, Pedro Romero, Daniel E. Speiser, Bernard A. Fox and Francesco M. Marincola

    Journal for ImmunoTherapy of Cancer 2016 4:62

    Published on: 18 October 2016

  5. Short report

    High-dose interleukin2 – a 10-year single-site experience in the treatment of metastatic renal cell carcinoma: careful selection of patients gives an excellent outcome

    VEGF-targeted therapy has become the mainstay of treatment for majority of mRCC patients. For most patients, benefit is short-lived and therefore treatment remains palliative in intent. HD IL2 is an effective ...

    S. Chow, V. Galvis, M. Pillai, R. Leach, E. Keene, A. Spencer-Shaw, A. Shablak, J. Shanks, T. Liptrot, F. Thistlethwaite and R. E. Hawkins

    Journal for ImmunoTherapy of Cancer 2016 4:67

    Published on: 18 October 2016

  6. Research article

    Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction

    Anti-PD-1 therapy is increasingly used in various advanced malignancies. Patients with baseline organ dysfunction are largely excluded from clinical trials. Therefore it is unclear whether anti-PD-1 therapy is...

    Bridgette A. Kanz, Megan H. Pollack, Romany Johnpulle, Igor Puzanov, Leora Horn, Alicia Morgans, Jeffrey A. Sosman, Suthee Rapisuwon, R. Martin Conry, Zeynep Eroglu and Douglas B. Johnson

    Journal for ImmunoTherapy of Cancer 2016 4:60

    Published on: 18 October 2016

  7. Research article

    5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers

    Resistance to chemotherapy is a major obstacle in the effective treatment of cancer patients. B7-homolog 1, also known as programmed death ligand-1 (PD-L1), is an immunoregulatory protein that is overexpressed...

    Lauren Van Der Kraak, Gaurav Goel, Krishnaveni Ramanan, Christof Kaltenmeier, Lin Zhang, Daniel P. Normolle, Gordon J. Freeman, Daolin Tang, Katie S. Nason, Jon M. Davison, James D. Luketich, Rajeev Dhupar and Michael T. Lotze

    Journal for ImmunoTherapy of Cancer 2016 4:65

    Published on: 18 October 2016

  8. Research article

    A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma

    High dose interleukin-2 (HD IL-2) can induce durable responses in a subset of patients leading to long-term survival. Immune checkpoint blockade (ICB) has demonstrated similarly durable responses in a larger p...

    Elizabeth I. Buchbinder, Anasuya Gunturi, Jessica Perritt, Janice Dutcher, Sandra Aung, Howard L. Kaufman, Marc S. Ernstoff, Girald P. Miletello, Brendan D. Curti, Gregory A. Daniels, Sapna P. Patel, John M. Kirkwood, Sigrun Hallmeyer, Joseph I. Clark, Rene Gonzalez, John M. Richart…

    Journal for ImmunoTherapy of Cancer 2016 4:52

    Published on: 20 September 2016

  9. Research article

    A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma

    Preclinical studies have shown synergy between radiation therapy and immunotherapy. However, in almost all preclinical models, radiation is delivered in single doses or short courses of high doses (hypofractio...

    Todd Crocenzi, Benjamin Cottam, Pippa Newell, Ronald F. Wolf, Paul D. Hansen, Chet Hammill, Matthew C. Solhjem, Yue-Yun To, Amy Greathouse, Garth Tormoen, Zeljka Jutric, Kristina Young, Keith S. Bahjat, Michael J. Gough and Marka R. Crittenden

    Journal for ImmunoTherapy of Cancer 2016 4:45

    Published on: 16 August 2016

  10. Research article

    Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma

    Ipilimumab (IPI), an anti-CTLA-4 antibody, and vemurafenib (VEM), a BRAF inhibitor, have distinct mechanisms of action and shared toxicities (e.g., skin, gastrointestinal [GI] and hepatobiliary disorders) that...

    Asim Amin, David H. Lawson, April K.S. Salama, Henry B. Koon, Troy Guthrie Jr, Sajeve S. Thomas, Steven J. O’Day, Montaser F. Shaheen, Bin Zhang, Stephen Francis and F. Stephen Hodi

    Journal for ImmunoTherapy of Cancer 2016 4:44

    Published on: 16 August 2016

  11. Research article

    Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial

    CAN-003 was a randomized, open-label, Phase 2 trial evaluating the safety, efficacy and immune outcomes of CVac, a mucin 1 targeted-dendritic cell (DC) treatment as a maintenance therapy to patients with epith...

    H. J. Gray, B. Benigno, J. Berek, J. Chang, J. Mason, L. Mileshkin, P. Mitchell, M. Moradi, F. O. Recio, C. M. Michener, A. Alvarez Secord, N E. Tchabo, J. K. Chan, J. Young, H. Kohrt, S. E. Gargosky…

    Journal for ImmunoTherapy of Cancer 2016 4:34

    Published on: 21 June 2016

  12. Research article

    Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab

    We have previously investigated neoadjuvant ipilimumab (ipi) for patients with locally/regionally advanced melanoma. That initial assessment of peripheral blood mononuclear cells (PBMC) showed a significant in...

    Janet Retseck, Robert VanderWeele, Hui-Min Lin, Yan Lin, Lisa H. Butterfield and Ahmad A. Tarhini

    Journal for ImmunoTherapy of Cancer 2016 4:38

    Published on: 21 June 2016

  13. Research article

    Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma

    Glioblastoma (GBM) is a poorly immunogenic neoplasm treated with focused radiation. Immunotherapy has demonstrated synergistic survival effects with stereotactic radiosurgery (SRS) in murine GBM. GITR is a co-...

    Mira A. Patel, Jennifer E. Kim, Debebe Theodros, Ada Tam, Esteban Velarde, Christina M. Kochel, Brian Francica, Thomas R. Nirschl, Ali Ghasemzadeh, Dimitrios Mathios, Sarah Harris-Bookman, Christopher C. Jackson, Christina Jackson, Xiaobu Ye, Phuoc T. Tran, Betty Tyler…

    Journal for ImmunoTherapy of Cancer 2016 4:28

    Published on: 17 May 2016

    The Erratum to this article has been published in Journal for ImmunoTherapy of Cancer 2016 4:74

  14. Short report

    Concurrent SPECT/PET-CT imaging as a method for tracking adoptively transferred T-cells in vivo

    The ability of T-cells to traffic to and penetrate tumors impacts the clinical efficacy of T-cell therapy therefore methods to track transferred T-cells in vivo are needed. In this preliminary report, we evalu...

    Sasha E. Stanton, Janet F. Eary, Edmond A. Marzbani, David Mankoff, Lupe G. Salazar, Doreen Higgins, Jennifer Childs, Jessica Reichow, Yushe Dang and Mary L. Disis

    Journal for ImmunoTherapy of Cancer 2016 4:27

    Published on: 17 May 2016

  15. Research article

    Prolonged intralymphatic delivery of dendritic cells through implantable lymphatic ports in patients with advanced cancer

    The currently-used modes of administration of immunotherapeutic agents result in their limited delivery to the lymph nodes and/or require repetitive ultrasound-guided nodal injections or microsurgical lymphati...

    Michal Radomski, Herbert J. Zeh, Howard D. Edington, James F. Pingpank, Lisa H. Butterfield, Theresa L. Whiteside, Eva Wieckowski, David L. Bartlett and Pawel Kalinski

    Journal for ImmunoTherapy of Cancer 2016 4:24

    Published on: 19 April 2016

  16. Research article

    Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study

    We previously reported that talimogene laherparepvec, an oncolytic herpes virus encoding granulocyte-macrophage colony-stimulating factor (GM-CSF), resulted in an objective response rate of 26 % in patients wi...

    Howard L. Kaufman, Thomas Amatruda, Tony Reid, Rene Gonzalez, John Glaspy, Eric Whitman, Kevin Harrington, John Nemunaitis, Andrew Zloza, Michael Wolf and Neil N. Senzer

    Journal for ImmunoTherapy of Cancer 2016 4:12

    Published on: 15 March 2016

  17. Research article

    Phase I study with ONCOS-102 for the treatment of solid tumors – an evaluation of clinical response and exploratory analyses of immune markers

    We conducted a phase I study with a granulocyte macrophage colony stimulating factor (GMCSF)-expressing oncolytic adenovirus, ONCOS-102, in patients with solid tumors refractory to available treatments. The ob...

    Tuuli Ranki, Sari Pesonen, Akseli Hemminki, Kaarina Partanen, Kalevi Kairemo, Tuomo Alanko, Johan Lundin, Nina Linder, Riku Turkki, Ari Ristimäki, Elke Jäger, Julia Karbach, Claudia Wahle, Matti Kankainen, Charlotta Backman, Mikael von Euler…

    Journal for ImmunoTherapy of Cancer 2016 4:17

    Published on: 15 March 2016

  18. Research article

    Cetuximab ameliorates suppressive phenotypes of myeloid antigen presenting cells in head and neck cancer patients

    Myeloid-derived suppressor cells (MDSC) and M2 monocytes/macrophages are two types of suppressive myeloid antigen presenting cells that have been shown to promote tumor progression and correlate with poor prog...

    Jing Li, Raghvendra M. Srivastava, Abhinav Ettyreddy and Robert L. Ferris

    Journal for ImmunoTherapy of Cancer 2015 3:54

    Published on: 17 November 2015

  19. Research article

    Inhibition of the angiopoietin/Tie2 axis induces immunogenic modulation, which sensitizes human tumor cells to immune attack

    The angiopoietin/Tie2 pathway is an attractive target for cancer therapy due to its well-known role in regulating angiogenesis. Trebananib, a recombinant peptide-Fc fusion protein, or peptibody, that binds to ...

    Italia Grenga, Anna R. Kwilas, Renee N. Donahue, Benedetto Farsaci and James W. Hodge

    Journal for ImmunoTherapy of Cancer 2015 3:52

    Published on: 17 November 2015

Previous Page Page 2 of 4 Next Page
JITC logo